Skip to main content
OLMA $7.02 -1.82%
OLMA logo
OLMA · Olema Oncology, Inc.
Track OLMA — free
$7.02 -0.13 (-1.82%) At close · Nov 20 Play latest call Q4 2024 earnings call transcript
Market Cap
$615.00M
Shares
87.61M
Volume · Nov 20 1.26M Avg daily vol (3M) 1.27M
All webcasts

Conference · 2026-11-10

Olema Oncology, Inc. (OLMA) November 10, 2026 Conference Transcript

Concluded Nov 10, 2026 Audio replay
Nov 10, 2026 25:07 26 turns
Period
2026-11-10
Runtime
25:07
Sources
2 artifacts

Transcript & audio

25:07 Audio
Paul Jang Analyst — Guggenheim

Well, let's get started with this next session. Thank you for joining us. My name is Paul Jang. I'm a biotech analyst with Guggenheim, and our next presenting company is Olima, and I'm very pleased to be joined by Sean Bowen, President and CEO. Sean, welcome.

Thank you, Paul.

Paul Jang Analyst — Guggenheim

Nice to be here. So maybe a good place to start for those who are newer to the story. Could you provide a quick introduction to the company and your pipeline?

Sure. So Olima Oncology is a company focused on breast cancer, primarily. ER positive, HER2 negative breast cancer, is by far the largest, about 70% of breast cancer. Obviously, breast cancer is the most common malignancy in women, second most common cause of cancer death. In women, and a huge unmet need in market. Our lead asset is palazestrin. It's a complete estrogen receptor antagonist and a selective estrogen receptor degrader. And that... That compound is in two Phase III trials right now. One is the second, third-line setting, so after patients have progressed on their CDK-4,6 inhibitor plus an AI, and that trial is called OPERO-1. The other arm is fulvestrin or eczemastane. It'll be mostly fulvestrin. And that trial reads out in... In Q1 of next year, there are several opportunities within that population. First of all, that's an aggregate is about a $5 billion a year market opportunity. And it's divided by a mutational status, right? So the most common resistance mutation to CDK4-6 plus AI is to activate the estrogen receptor. So that's ESR1 mutant subset. That's about 40% of patients, a $2 billion market on its own. And there are other compounds that have had some success there, but all of them, the increase in PFS is about two months. We saw 7.3 months in our Phase 2, so if we can get in that range, always a question of is Phase 2 replicated in Phase 3, then we would potentially be... We're distinguishing ourselves by greater efficacy, greater prolongation of PFS in the mutant setting. And then the wild-type setting, the remaining 60%, $3 billion opportunity, is really unaddressed. No one's shown any treatment effect there. We had 5.5 months in phase two. And again, if we are able to replicate something in that range, we may be the first compound to be able to address that ESR1 wild-type post-CDK4-6. The other than the. Phase 2 data I cited. The reason really to believe here is we have very high exposure in addition to being a complete estrogen receptor antagonist. The other ongoing and enrolling very robustly phase 3 trial is called OPRAO2. That is a first-line setting metastatic in combination with Qiskali. So that's Qiskali plus palzestrin versus Qiskali plus letrozole, the standard of care AI. And in its current design, that's 1,000-patient trial. We may change the size of that trial. We're going to see the Serena 4 data from AstraZeneca in December. It looks like the control arm may be performing a little better than historical, so that would lead us to potentially add patients to the trial. The advantages we have here, we saw over a year median PFS post-CDK46 plus AI with our ribo-palizestrant combo. The advantage we have here is that we don't enhance toxicity. We don't have to dose-modify either agent in combination, and obviously we're the only company that's gone into this setting with a new endocrine agent in the context of combination with Kiskali, Which is the standard of care because of its survival benefit. And that's a $10 billion-plus market opportunity in that first-line setting. Other than our data, the Roche-Persevera trial with palbociclip showed a clear signal that there's activity that you can do better than an AI. It had some design flaws. They also have a much lower exposure of their agent, and so I think we, again, with the Phase II data, feel confident that we have an opportunity to... Do better than the AI in the Qiskali combination. Then we have a phase 1-2 agent, which is a CAT 6 inhibitor, OP3136. We have presented monotherapy data. Interestingly, we think the lead molecules Pfizer, which clearly has activity in breast cancer with fulvestrin, we saw monotherapy activity in breast cancer, interestingly, and different than Pfizer. We also saw monotherapy activity in prostate cancer, castration-resistant prostate cancer. So we are now expanding into prostate cancer in combination with Nubeca. We don't have DLTs yet. We don't have an MTD, but we are combining with fulvestrant and with palazestrant, so the lead molecule. The palazestrant combo preclinically looks more active than anything we've seen, including the fulvestrant combo. We're going to show the first fulvestrant combo data at San Antonio. As a late-breaking abstract, and so that'll be some dose escalation data, but you will see early efficacy as well as combinability in that context. So we do feel like there's a real opportunity to differentiate by efficacy by tolerability, particularly cytopenia's rate of cell count decreases. And then, obviously, the combination with Nubeca and prostate cancer is something that will begin enrollment very soon.

Paul Jang Analyst — Guggenheim

Okay, great. So lots of topics to cover, obviously. So maybe starting with Opera 01. So as you alluded to, there's been a history of this sort of class of agents in the setting where ESR 01 wild type has sort of been an unaddressed segment. So you alluded to the pharmacology and some of the clinical data, but what really gives you the most confidence that you could work potentially in the segment compared to others in the class?

Yeah, I mean, I do think the phase two data is probably the greatest. That's a factor that gives us confidence that there's an opportunity here. Just to remind everybody, what happens in the context of the fulvestrant or eczemestane is really in this population, two, maybe three months is what you get as a median PFS with those agents. So, to be able to extend... By a couple months or even, you know, close to that would be really differentiating and create a meaningful opportunity there. So that's obviously what's being tested in OPRA-01 in addition to activity in the ESR-1 mutant subset. Why would you have activity there when others haven't? Again, not all of the molecules, in particular, the lead molecule there, or SIRDU, is not a complete estrogen receptor antagonist. It's a CIRM. So it's actually turning on the wild-type receptor in some contexts, and you obviously don't want to do that in any context in ER-positive breast cancer. In addition, there are others that are complete antagonists, but our exposure is much higher. So we think that occupying the receptor completely, turning it off completely 24-7 for the duration of this therapy is very important. Just a reminder, estrogen receptor is a ligand-regulated transcription factor in the wild-type setting, and so it's a highly amplified growth and proliferation signal, so you really need to keep it turned off all the time.

Paul Jang Analyst — Guggenheim

Okay. And can you remind us of the statistical plan for evaluating ESR1 mutant versus wild type?

Yeah, it's a little complicated. So we haven't disclosed the statistical plan. I can talk about the performance characteristics. So going into the trial, it looks the same regardless of your ESR1 status. You've post CDK4-6 plus AI progression. You're randomized to palzestrin or fulvestrin or What we do is we test for the ESR1 mutational status and then stratify. When you get to the analysis plan, it almost looks a little bit like two trials, right? So the ESR1 mutant and ESR1 wild type subsets are analyzed independently. This is unique. None of the other trials in the space have done it this way. And then you can, there are three ways to have a positive trial. Obviously, success in both of them. Based on hazard ratio meeting the critical p-value is clearly a success. You can also have a positive trial with... Mutant hitting and wild-type not, or, and this doesn't necessarily make biological sense, but statistically you could have wild-type hit and mutant not, and you would have a positive trial.

Paul Jang Analyst — Guggenheim

Okay. And then you alluded to the top line is coming fairly soon in the first quarter of next year. So what should we expect for the top line in terms of the amount of data that we'll see at that time?

Yeah, yeah. So in the first quarter, I don't think you'll see a whole lot of data, but definitely, obviously, that'll wait for a scientific presentation at a meeting. But obviously, this is a very important piece of information for Olima, and so we will definitely have a press release. And, you know, we'll seek to be transparent about what were the outcomes of the trial, specifically in the ESR-1 mutant and the ESR-1 wild type subsets. So I think that you can expect the disclosure will give enough information to be able to assess. How we did in the trial. I think then there's a lot of details that will come subsequently in the context of a medical meeting.

Paul Jang Analyst — Guggenheim

Okay. And in the scenario that you only succeed in the ESR-1 mutant segment, how would you go about, how do you view the commercial opportunity in light of the competition in the space?

Right. So again, the market is probably at least $2 billion there. So It is not an insignificant market. It is competitive, right? Our surduced there first, and now in Lunestrant, we see it's coming up around almost $300 million annualized as the second agent coming in there. I think there is a very obvious opportunity here, which is... Which is to do better than two months extension of PFS, which is all that has been seen with any of these agents. There are other factors in there, too. There are tolerability factors, and lunestrant has diarrhea as a side effect. That is not a great quality of life attribute to have. But I think... I really think efficacy is the biggest driver, and it's in pretty much any cancer indication.

Paul Jang Analyst — Guggenheim

Sure, yeah, makes sense. Okay, then you alluded to the other phase three study, OPERA02, and as well as some of the sort of lateral updates in this space, specifically Persevera and then Serena IV, which were unsuccessful phase three studies. So I'm just curious how, if at all, do these results affect your view on OPERA02, Or perhaps how the trial is going to be conducted, and can you speak to any earlier data from palizestrin that give you confidence on this study working where others may have not?

Yeah, so we haven't seen the data from Serenaphor yet, so that will come actually at San Antonio. So I can't... Comment in detail on that other than that the trial was negative, as you said. There's some somewhat cryptic, like, superior numerically or something like that in their press release. We have seen the Persevera data. Persevera is an interesting... Trial in that while it did miss, it was quite close. It just missed the hazard ratio critical value by a few hundredths. And it showed a very clear trend in the direction that gerodestrant, the Roche molecule with Ibrant's was better than Ibrant's plus AI. The actual difference in PFS was about five months. If you'd hit the hazard ratio, that's approvable. That would definitely change the standard of care. They didn't quite make the hazard ratio. Now, there are... We learned something from the design of that trial. It doesn't lead to a change in OPERO2. Specifically, they included patients who had a treatment-free interval of less than one year post their adjuvant therapy. These are endocrine-resistant patients by definition, and they did quite poorly and probably did not have a good effect on this near-miss. Now, the conclusion is you shouldn't enroll those patients in the trial. Well, we don't enroll those patients in OPERO2. By the way, AZ didn't in Serena 4 either. So there is a lesson there, but we don't really have to change OPERO2 to respond to it. The other thing I would say is I think this trend to us is very encouraging. You wouldn't need to do much better. In order to be in a positive trial, and the actual treatment effect is large enough to drive approval and standard and change in usage patterns. So, in that respect, we view Persevera as very much supportive of OPERO2, particularly because our data in combination with ribociclib looks better. So we think already the superior exposure receptor occupancy combinability is showing up in our data. There is something interesting that we saw in Persevera that we will look for in Serena 4, which is it does look like the control arm may be outperformed historical. This is really common in oncology, right? Oncologists are very good at managing side effects. They're very good at decreasing discontinuations, dose reductions, maintaining dose intensity as they learn how to give a therapy. So if we see that again, we probably would consider increasing the size of OPERO2 to have more patients, potentially more events. Um, to be able to analyze. So that is the one question that I think we're still remaining to answer. It's part of why we haven't really provided timeline guidance on the readout of OPERO2, because if we provide guidance and then we change the trial and enroll more patients, it's rolling very well. So I don't think that'll have a big impact, but it obviously it does, it does change, um, your forecast.

Paul Jang Analyst — Guggenheim

Yeah, it makes sense. And I guess we'll see the full data, as you mentioned, at San Antonio. And you'll also have some updates for Paola at San Antonio. So could you sort of just high-level talk about what you're going to do?

Yeah, the two things we're going to present at San Antonio, it's more combination data. So we think a really important distinguishing attribute of palzestrin is that it combines with other targeted agents very broadly. So if we go back in breast cancer and remind everybody, the treatment objective in metastatic breast cancer is to put off chemotherapy as long as possible. Unfortunately, none of these treatments are curative in the metastatic setting. So what you're doing is you're trying to control the disease, avoid progression as long as possible, preserve quality of life, and put off chemotherapy as long as possible. And so in the first-line setting, the standard of care is very Straight forward. It's Kiskali plus AI, OPERO2. We're trying to switch it to Kiskali plus palazestrin. After that, it becomes much more heterogeneous how you treat patients. You may test for mutation, AKT, PI3 kinase, give a targeted therapy there, ESR1, right? You may give monotherapy, endocrine therapy, or A targeted therapy plus endocrine therapy. Always give endocrine therapy. So we think that being combinable with these various different agents without having to reduce the dose of either and without enhancing the toxicity of the combination is a really important distinguishing attribute. And so at San Antonio, you will see two new agents we have combined with but not presented data on. One is an older agent, the mTOR inhibitor Everlimus. And I think that people will find that data set very interesting, representing the mutant versus wild type in that context. The other agent is a newer agent. It's a tormacyclyb, which a tormacyclyb is the CDK4 selective molecule from Pfizer that is in phase three. In the first-line setting, that is comparing CDK46 of investigators' choice. We think it'll be mostly ribocichlid versus atormocichlid, both in combination with AI. And so what we're doing there is, one, showing combinability, but also looking at the life cycle of where is the treatment paradigm potentially going.

Paul Jang Analyst — Guggenheim

Okay. Then maybe sticking on San Antonio and the CAT6 inhibitor now, so you've also alluded to an update at San Antonio. So maybe contextualize this first with what you've shown so far. You had some data at ASCO for monotherapy, and what were the key highlights there, and then what will you have at San Antonio?

Yeah, so the data at ASCO was, as you said, monotherapy. It was dose escalation. With the monotherapy, we showed very clearly that we have single-agent activity in metastatic ER-positive, HER2-negative breast cancer. This is actually, through the Pfizer program, is essentially a validated target mechanism of action in that population. We go on and show that, yes, we do also have activity as a monotherapy. In addition, it looks like we may have less. Adverse events, particularly the cytopenias and neutropenia, which, you know, Pfizer at their phase 3 dose has had in phase 2 50-0% dose reductions or discontinuations due to AEs, which mostly was cytopenias. We don't think we have that kind of level of cytopenias that leads to We're altering the exposure, and in addition, you know, as I said, we're now at 80 milligrams daily. We started at 2. We don't have an MTD yet, so we are going to have to figure out how we choose dose for going forward. The other thing that we saw that was distinguishing is Pfizer also looked at castration-resistant prostate cancer. We saw single-agent activity there, which is, again, unique, and that's led to this Nubeca combination, a collaboration with Bayer, which will start in the coming couple of months. The data we're going to add in to present at San Antonio is the fulvestrin combination. So in breast cancer, we have two combinations enrolling right now with OP3136, the CAT-6 inhibitor. One is fulvestrin, and the other is palizestrin. So that's unique. We're the only people who can combine with palizestrin. The preclinical data suggests that even with the Pfizer molecule, The addition of palizestrant rather than fulvestrant significantly enhances the activity of the combination. That data will come... Mid-year next year with palvestrin, but the fulvestrin initial dose escalation data. We're going to show, so you'll get early efficacy at these multiple-dose levels in the context of overall response rate, right? That's what we have. We don't have enough time to really have a duration endpoint. You'll get tolerability of the combination, and I think the other thing is people will, of course, go back and look at what happened with the Pfizer molecule at this stage. They had about a 30% response rate. You'll be able to look at our response rate, again, multiple dose levels, but also in more heavily pretreated patients. So I think when you take that context, we feel very confident in where 3136 is going. I think the big question is, do we replicate the preclinical data with palzestrin in the clinic? And we'll have to wait a little bit for that.

Paul Jang Analyst — Guggenheim

Sure. And then on the comparison with Pfizer's molecule, you mentioned less cytopenias, has better tolerability. So what is the rationale behind that? Is it a matter of selectivity or pharmacology?

We think it might be a matter of selectivity. So the Pfizer molecule... Hits cat 6, cat 6a and b, and also at the exposures they get hits cat 7. We hit cat 6a, b, and 7 as well at our exposures. We've dialed back considerably cat 5 and cat 8. And a Pfizer molecule at their phase 3 dose hits those two. So we are narrowing the selectivity somewhat. And we hypothesize that that may be contributing to less cytopenias occurring. The other side effect that occurs with this class of molecules is a taste alteration, dyskusia. And pretty much everyone gets that. Not just the cat. Six inhibitors, but even other epigenetic molecules. When HDACs were used, EZH2, these others run into this as well.

Paul Jang Analyst — Guggenheim

Okay, got it. Okay, and then on the prostate cancer combo, which you mentioned is kicking off, so when can we sort of expect, what's the sort of cadence of enrollment, and we can expect some data from this one?

Yeah, I mean, I think, you know, we'll do a... A little bit of dose escalation. Obviously, the Nubeca dose is set, and we're not starting at 2 milligrams with 3136 anymore. So there will be some dose escalation, and then we'll figure out where we're going to expand. I think the soonest we could get data to share is probably later next year. From that, we anticipate it'll enroll quickly. All our 3136 cohorts have, but obviously when you're doing dose escalation, you enroll a number of patients. You pause to evaluate for toxicity, and then you go back and dose escalate again. So it is not the fastest. It's when you get a dose and you can expand that you really are generating more data.

Paul Jang Analyst — Guggenheim

Okay, so a lot of moving parts, obviously. So maybe with the last minute, could you summarize your cash runway as well as your key upcoming milestones, Opera 01, San Antonio, and sort of what else we would expect?

Yeah, so we did our Q2 results today. Our cash on hand is about $414 million. That runway takes us nicely into 2028. We think, actually, if obviously Opera 01 is positive in the range of through the launch of that program, assuming positive data, again. And that's with OPERO1 and OPERO2, both of these trials ongoing in the current 3136 activities. So we feel quite confident. Now with Opera 01, we intend to launch in the United States, file and launch in the United States. We can file elsewhere in the world, but we do not intend to launch and promote. So again, assuming a positive trial, we would seek a collaborator in order to do that. But of course, and it makes sense with data in Q1, our assumption is potential collaborators will want to wait to the data to see it in order to make those decisions.

Paul Jang Analyst — Guggenheim

Okay, great. So I think we're up on our time, so we'll wrap it there. But I want to thank you again, Sean, for joining us.

Thank you, Paul. Appreciate it.

Analyst Q&A · 1 question
Full-screen source Call document